Literature DB >> 21699609

Neocortical atrophy in Machado-Joseph disease: a longitudinal neuroimaging study.

Anelyssa D'Abreu1, Marcondes C França, Clarissa L Yasuda, Bruno A G Campos, Iscia Lopes-Cendes, Fernando Cendes.   

Abstract

BACKGROUND/
PURPOSE: Previous imaging studies in the Machado-Joseph disease (MJD/SCA3) have mostly concentrated on the cerebellum and brainstem. Our goal was to perform a whole brain longitudinal evaluation.
METHODS: We included 45 patients and 51 controls, who underwent two brain magnetic resonance imaging and magnetic resonance spectroscopy (mean interval of 12.5 ± 1.5 months). We used voxel-based morphometry (VBM) and the MarsBar analysis toolbox to extract grey matter density (GMD) values from regions of interest. We used a linear regression model and a general linear model to correlate GMD with clinical markers, and paired t-test for the longitudinal evaluation.
RESULTS: We observed decreased GMD (P < .01) at frontal, parietal, temporal and occipital lobes, subcortical grey matter, cerebellum, and brainstem. White matter atrophy was restricted to the cerebellum. Age, CAG, and disease duration predicted GMD in different areas, but age and CAG were the most important predictors. The longitudinal analysis failed to demonstrate changes. Changes in regions other than the cerebellum appeared to contribute significantly to the final International Cooperative Ataxia Rating Scale score.
CONCLUSION: We confirmed cortical involvement in MJD/SCA3. The most important factors in predicting GMD were age and CAG. The lack of progression of atrophy may indicate floor effect and/or short duration of follow-up.
© 2011 by the American Society of Neuroimaging.

Entities:  

Mesh:

Year:  2011        PMID: 21699609     DOI: 10.1111/j.1552-6569.2011.00614.x

Source DB:  PubMed          Journal:  J Neuroimaging        ISSN: 1051-2284            Impact factor:   2.486


  32 in total

Review 1.  Toward understanding Machado-Joseph disease.

Authors:  Maria do Carmo Costa; Henry L Paulson
Journal:  Prog Neurobiol       Date:  2011-11-23       Impact factor: 11.685

2.  Cognitive deficits in Machado-Joseph disease correlate with hypoperfusion of visual system areas.

Authors:  Pedro Braga-Neto; Lívia Almeida Dutra; José Luiz Pedroso; André C Felício; Helena Alessi; Ruth F Santos-Galduroz; Paulo Henrique F Bertolucci; Mário Luiz V Castiglioni; Rodrigo Affonseca Bressan; Griselda Esther Jara de Garrido; Orlando Graziani Povoas Barsottini; Andrea Jackowski
Journal:  Cerebellum       Date:  2012-12       Impact factor: 3.847

3.  In Vivo Molecular Signatures of Cerebellar Pathology in Spinocerebellar Ataxia Type 3.

Authors:  Maria do Carmo Costa; Maria Radzwion; Hayley S McLoughlin; Naila S Ashraf; Svetlana Fischer; Vikram G Shakkottai; Patrícia Maciel; Henry L Paulson; Gülin Öz
Journal:  Mov Disord       Date:  2020-07-04       Impact factor: 10.338

4.  Psychosis in Machado-Joseph Disease: Clinical Correlates, Pathophysiological Discussion, and Functional Brain Imaging. Expanding the Cerebellar Cognitive Affective Syndrome.

Authors:  Pedro Braga-Neto; José Luiz Pedroso; Ary Gadelha; Maura Regina Laureano; Cristiano de Souza Noto; Griselda Jara Garrido; Orlando Graziani Povoas Barsottini
Journal:  Cerebellum       Date:  2016-08       Impact factor: 3.847

Review 5.  Fragile X-associated tremor/ataxia syndrome: phenotypic comparisons with other movement disorders.

Authors:  Erin E Robertson; Deborah A Hall; Andrew R McAsey; Joan A O'Keefe
Journal:  Clin Neuropsychol       Date:  2016-08       Impact factor: 3.535

Review 6.  Spinocerebellar ataxias: prospects and challenges for therapy development.

Authors:  Tetsuo Ashizawa; Gülin Öz; Henry L Paulson
Journal:  Nat Rev Neurol       Date:  2018-10       Impact factor: 42.937

7.  Selective Procedural Memory Impairment but Preserved Declarative Memory in Spinocerebellar Ataxia Type 3.

Authors:  Zohar Elyoseph; Matti Mintz; Eli Vakil; Roy Zaltzman; Carlos R Gordon
Journal:  Cerebellum       Date:  2020-04       Impact factor: 3.847

8.  Executive dysfunction in patients with spinocerebellar ataxia type 3.

Authors:  Itaru Tamura; Asako Takei; Shinsuke Hamada; Hiroyuki Soma; Michio Nonaka; Sanae Homma; Fumio Moriwaka
Journal:  J Neurol       Date:  2018-05-03       Impact factor: 4.849

9.  Antisense oligonucleotide therapy rescues aggresome formation in a novel spinocerebellar ataxia type 3 human embryonic stem cell line.

Authors:  Lauren R Moore; Laura Keller; David D Bushart; Rodrigo G Delatorre; Duojia Li; Hayley S McLoughlin; Maria do Carmo Costa; Vikram G Shakkottai; Gary D Smith; Henry L Paulson
Journal:  Stem Cell Res       Date:  2019-07-16       Impact factor: 2.020

10.  Widespread neuronal damage and cognitive dysfunction in spinocerebellar ataxia type 3.

Authors:  Tátila Martins Lopes; Anelyssa D'Abreu; Marcondes Cavalcante França; Clarissa Lin Yasuda; Luiz Eduardo Betting; Adriana Bastos Samara; Gabriela Castellano; Júlio César Somazz; Marcio Luiz Figueredo Balthazar; Iscia Lopes-Cendes; Fernando Cendes
Journal:  J Neurol       Date:  2013-06-18       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.